Torque Teno Virus Control by the Classical Pathway of Complement Activation-A Retrospective Analysis From a First-in-Human Trial Utilizing Sutimlimab.

Autor: Kapps S; Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria., Mühlbacher J; Department of Surgery, Division of Visceral Surgery, Medical University of Vienna, Vienna, Austria., Kulifaj D; bioMérieux SA, Parc Technologique Delta Sud, Verniolle, France., Courjal S; bioMérieux SA, Parc Technologique Delta Sud, Verniolle, France., Eskandary F; Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria., Schiemann M; Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria., Jilma B; Department of Clinical Pharmacology, Medical University of Vienna, Vienna, Austria., Böhmig GA; Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria., Bond G; Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria., Wahrmann M; Department of Medicine III, Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria.
Jazyk: angličtina
Zdroj: Journal of medical virology [J Med Virol] 2024 Nov; Vol. 96 (11), pp. e70039.
DOI: 10.1002/jmv.70039
Abstrakt: Torque Teno virus (TTV) load is linked with the functionality of its host's immune system and has been proposed as a potential monitoring tool for immune-modulating therapy. However, the immunological mechanisms of TTV control are incompletely understood. To assess the effect of the classical complement pathway on TTV, 64 healthy volunteers and 10 kidney transplant recipients treated with the anti-C1s antibody sutimlimab were analyzed for serum TTV copy numbers (c/mL) by qPCR. Overall, a correlation was observed between the decrease in complement activity caused by sutimlimab and the TTV load increase (ρ = -0.367, p < 0.001). Subgroup analysis indicated a trend toward TTV load increase in healthy volunteers following the highest sutimlimab dose compared to baseline (100 mg/kg body weight; median 3.5 log 10 c/mL, interquartile range [IQR] 2.8-4.4 vs. 2.9 log 10 c/mL, 0.8-3.5; p = 0.063). Administering multiple lower doses (30 mg/kg) also showed a trend toward TTV load increase in healthy volunteers (1.8 log 10 c/mL, 0-2.3 vs. 1.9, 1.3-2.8; p = 0.054) and a significant increase in transplant recipients (3.5 log 10 c/mL, 3.0-6.1 vs. 4.1, 3.5-6.4; p = 0.004). This report suggests a role for the classical complement pathway in controlling TTV load.
(© 2024 The Author(s). Journal of Medical Virology published by Wiley Periodicals LLC.)
Databáze: MEDLINE
Externí odkaz: